Per Reuters, Novo Holdings, the controlling shareholder of Novo Nordisk, has announced plans to buy a controlling stake of about 60% in Single Use Support, an Austrian life science tools company.
 
Single Use Support provides advanced fluid management solutions around single-use technologies for the Biopharma Industry to increase patient safety. Its product solutions cover the whole liquid management process starting from packaging in bags, protecting with save shells, filling via manifold assemblies and fill/filtration platforms, up to cold chain management with controlled freezing & thawing, ultra cold freezing and reliable shipping.
 
This acquisition is part of Novo Nordisk’s focus on companies that provide services to the pharmaceuticals industry. It comes months after Novo Holdings agreed to acquire Catalent in an all-cash transaction that valued Catalent at $16.5 billion on an enterprise value basis.
 
According to Johan Hueffer, senior partner in principal investments at Novo Holdings, Single Use Support “got a huge boost” during the Covid-19 pandemic from business from Moderna. He believes the company still has a lot of potential for continued growth.
 
Novo Holdings’ aim is to help take Single Use Support and its products to more customers in Europe and around the globe.